Skip to main content
OpenTrials
Completed

NCT Number: NCT02716285

Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery

Peppermint oil has shown to be effective in the treatment of Irritable Bowel Syndrome (IBS) symptoms in several meta-analyses. However, the level of evidence is moderate and peppermint oil remains relatively under-used in IBS. Therefore, the investigators will conduct a multicenter randomized, placebo controlled trial to investigate the effects of an eight-week peppermint oil treatment in IBS patients according to current European Medicines Agency (EMA) / US Food and Drug Administration (FDA) guidelines. To improve efficacy and to reduce side effects, the investigators aim to study the use of a new peppermint oil formulation, a colon-targeted-delivery capsule that will release the oil in the (ileo-) colonic region specifically.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Gelderse Vallei Hospital, Ede, Gelderland, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years;
  • Diagnosed with Irritable Bowel Syndrome according to the Rome IV criteria:

(Recurrent abdominal pain, at least 1 day/week for the last 3 months; Symptom onset at least 6 months prior to diagnosis; Associated with two or more of the following:

  • Pain related to defecation;
  • Pain associated with a change in frequency of stool;
  • Pain associated with a change in form (appearance/consistency) of stool
  • Based on the medical history and previous examination, no other causes for the abdominal complaints can be defined. Especially no history of:
  • Inflammatory Bowel Disease;
  • Celiac Disease;
  • Thyroid dysfunction (if not well-regulated). If alarm symptoms (including unexplained rectal blood loss or weight loss) are present, a colonoscopy has been performed and was negative for other causes.
  • Women in fertile age (<55 years old) must use contraception or be postmenopausal for at least two years.
  • Average worst abdominal pain score (on 11-point NRS) of > 3, during the two-week run-in period.

Exclusion criteria

  • Insufficient fluency of the Dutch language;
  • Any previous use (also incidental use) of peppermint oil capsules in the last 3 months prior to inclusion (the use of peppermint tea, menthol candy etc. is allowed);
  • The inability to stop regular use of medication affecting the gastro-intestinal system (such as Non Steroidal Anti Inflammatory Drugs (NSAID), laxatives, prokinetics, opioids, smasmolytics and anti-diarrhoeal drugs). This use should be halted at least 1 week before enrollment into the run-in period;
  • The use of 1 antidepressant drug is allowed, providing dosing has been stable for > 6 weeks before enrollment;
  • The use of 1 proton pump inhibitor (PPI) is allowed, providing dosing has been stable > 6 weeks before enrollment;
  • Previous major abdominal surgery or radiotherapy interfering with gastrointestinal function:
  • Uncomplicated appendectomy, cholecystectomy and hysterectomy allowed unless within the past 6 months;
  • Other surgery upon judgment of the principle investigator;
  • History of liver disease, cholangitis, achlorhydria, gallstones or other diseases of the gallbladder/biliary system;
  • Pregnancy, lactation;
  • Using drugs of abuse;
  • Known allergic reaction to peppermint.

Treatment and study plan

Ileocolonic release peppermint oil

Drug

Peppermint oil, menthae piperitae aetheroleum

Placebo

Drug

Placebo capsule, containing microcrystalline cellulose

Small intestinal release peppermint oil

Drug

Peppermint oil, menthae piperitae aetheroleum

Other names: Tempocol

Primary outcomes

  1. Abdominal pain response rate after 8 weeks of treatment

    Time frame: 8 weeks

    A responder is defined as a patient who experiences at least a 30 percent decrease in the weekly average of worst daily abdominal pain (measured daily, on an 11 point NRS) compared to baseline weekly average in at least 50 percent of the weeks in which the treatment in given.

  2. Degree of relief response rate after 8 weeks of treatment.

    Time frame: 8 weeks

    A responder is defined as a patient who experiences a weekly relief of 1 or 2 (on a 7 point NRS) in at least 50 percent of the weeks in which treatment is given.

Secondary outcomes

  1. Global symptom improvement

    Time frame: 8 weeks

    As determined by IBS-SSS (IBS symptom severity scale)

  2. Abdominal Discomfort

    Time frame: 8 weeks

    As determined by symptom diary

  3. Bloating

    Time frame: 8 weeks

    As determined by IBS-SSS (IBS - symptom severity scale)

  4. Regurgitation

    Time frame: 8 weeks

    As determined by symptom diary

  5. Nausea

    Time frame: 8 weeks

    As determined by symptom diary

  6. Urgency

    Time frame: 8 weeks

    As determined by symptom diary

  7. Abdominal cramps

    Time frame: 8 weeks

    As determined by symptom diary

  8. Average stool frequency and consistency

    Time frame: 8 weeks

    Measured by bristol stool chart

  9. Indirect costs

    Time frame: 8 weeks, 3 and 6 months

    Determined by Production Cost Questionnaire (PCQ) questionnaire

  10. Direct costs

    Time frame: 8 weeks, 3 and 6 months

    Determined by Medical Cost Questionnaire (MCQ) questionnaire

  11. General Quality of Life

    Time frame: 8 weeks, 3 and 6 months

    As determined by Euro-Qol-5D (EQ-5D)

  12. IBS related Quality of Life

    Time frame: 8 weeks, 3 and 6 months

    As determined by IBS-Quality of life questionnaire (IBS-QoL)

  13. Use of Over the counter medication and rescue medication

    Time frame: 8 weeks

    Number of drugs taken as rescue medication (This is not an intervention)

  14. Number and severity of side effects

    Time frame: 8 weeks

    Determined by daily diary

  15. Responder rates following discontinuation of treatment at 3 and 6 months, different thresholds for the responder analysis of abdominal pain (e.g. 40 and 50 percent improvement);

    Time frame: 3 and 6 months after discontinuation of treatment

  16. Responder rates when missing are interpreted as "no effect"

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Acronym: PERSUADE

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Mar 23, 2016
Registry last updated
Nov 2, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.